Gastrointestinal Cancer

Top Story

Companies collaborate to evaluate immunotherapy regimen for colorectal cancer

June 22, 2017

Three companies — eFFECTOR Therapeutics, Pfizer and Merck KGaA — entered a clinical collaboration to evaluate the combination of eFT508 and avelumab for patients with microsatellite stable colorectal cancer.

eFT508 (eFFECTOR Therapeutics) is a highly selective oral inhibitor of MNK1/2 kinases that mediate tumor immune evasion and are activated downstream of MEK and MAPK signaling.

In the Journals

Colorectal cancer task force ranks screening tests, suggests earlier screening in blacks

June 21, 2017
The U.S. Multi-Society Task Force on Colorectal Cancer Screening has released new recommendations that rank screening options for average-risk individuals, acknowledge…
In the Journals

Early decompensation predicts mortality in successfully treated HCC

June 21, 2017
The most significant risk factor for mortality in patients with hepatitis C-related cirrhosis and successfully treated hepatocellular carcinoma was hepatic…
Point/Counter

Do the benefits of a feeding tube outweigh the risks for a malnourished patient with cancer treated with curative intent?

HemOnc Today, June 25, 2017
POINT Malnutrition — suspected to occur in 40% to 80% of patients with cancer — can negatively affect response to treatment; increase treatment-related toxicity;…
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News Coverage

VIDEO: Merge of immunotherapy, genomics leads to personalized treatment

June 23, 2016
More »
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »

Companies collaborate to evaluate immunotherapy regimen for colorectal cancer

June 22, 2017
Three companies — eFFECTOR Therapeutics, Pfizer and Merck KGaA — entered a clinical collaboration to evaluate the combination of eFT508…

In the Journals

Colorectal cancer task force ranks screening tests, suggests earlier screening in blacks

June 21, 2017
The U.S. Multi-Society Task Force on Colorectal Cancer Screening has released new recommendations that rank screening options for average-risk…

In the Journals

Early decompensation predicts mortality in successfully treated HCC

June 21, 2017
The most significant risk factor for mortality in patients with hepatitis C-related cirrhosis and successfully treated hepatocellular carcinoma was…

Point/Counter

Do the benefits of a feeding tube outweigh the risks for a malnourished patient with cancer treated with curative intent?

HemOnc Today, June 25, 2017
POINT Malnutrition — suspected to occur in 40% to 80% of patients with cancer — can negatively affect response to treatment; increase…

FDA News

FDA grants orphan drug designation to IT-139 for pancreatic cancer

June 20, 2017
The FDA granted orphan drug designation to IT-139 for the treatment of pancreatic cancer, according to the drug’s manufacturer. “IT-139…

In the Journals Plus

First-line cetuximab, bevacizumab show similar outcomes in colorectal cancer

June 20, 2017
The addition of cetuximab or bevacizumab to a first-line chemotherapy regimen demonstrated similar OS, PFS and response rates in patients with…

In the Journals

Fecal immunochemical test may be viable screening option for colorectal cancer

June 19, 2017
Fecal immunochemical testing for colorectal cancer demonstrated high overall diagnostic accuracy indicating it as a viable, safe, simple, low-cost…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

Curbside Consultation

EUS Utility Varies Among Gastrointestinal Cancers

Healio Gastroenterology, June 2017
Thomas J. Savides, MD
A: Gastrointestinal endoscopic ultrasound (EUS) is an important tool for cancer staging because many treatment algorithms are determined by EUS tumor…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

More Headlines »
Advertisement
Advertisement